Clinical Trial Update: Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating adjuvant docetaxel and estramustine phosphate for high-risk localized prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Estramustine phosphate (estramustine phosphate)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED